文献速递瓣膜外科

RESILIA组织生物瓣主动脉瓣置换术后5年最终结局

Final 5-year outcomes following aortic valve replacement with a RESILIA™ tissue bioprosthesis.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

本研究为前瞻性、非随机、单臂研究,纳入133例在波兰2个中心植入RESILIA主动脉生物瓣的患者,每年评估临床结局和血流动力学性能至术后5年。结果显示该瓣膜安全性良好,5年内无结构性瓣膜退化事件,血流动力学性能优异,5年平均压差为14.8 ± 7.6 mmHg,有效瓣口面积为1.4 ± 0.5 cm2。

要点

  • RESILIA主动脉生物瓣术后5年无结构性瓣膜退化事件。
  • 5年平均压差14.8 ± 7.6 mmHg,有效瓣口面积1.4 ± 0.5 cm2。
  • 早期全因死亡率2.3%,晚期全因死亡率3.2%/患者年。

核心结论

  • RESILIA组织生物瓣在5年随访中表现出良好的安全性和优异的血流动力学性能。

研究设计与样本

  • 前瞻性、非随机、单臂研究,纳入133例2011年7月至2013年2月在波兰2个中心植入RESILIA主动脉生物瓣的患者。

主要发现

  • 平均随访4.2 ± 1.5年,早期(≤30天)全因死亡率为2.3%(N=3),晚期(>30天)全因死亡率为3.2%/患者年(N=18)。
  • 早期事件包括3例(2.3%)血栓栓塞;晚期瓣膜相关事件包括1例心内膜炎导致再次手术和1例瓣膜血栓形成。
  • 整个研究期间无结构性瓣膜退化事件。
  • 5年平均压差为14.8 ± 7.6 mmHg,有效瓣口面积为1.4 ± 0.5 cm2,较基线值明显改善。
  • 基线时所有纽约心脏协会(NYHA)III级患者和大多数II级患者在5年时心功能分级改善。

临床怎么用

  • RESILIA组织生物瓣在5年内显示出良好的安全性和血流动力学性能,可作为主动脉瓣置换的选项之一。

局限性

  • 研究为非随机单臂设计,样本量有限(133例),随访时间5年,需进一步研究证实长期耐久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Long-term durability of bioprosthetic valves is predominantly limited by structural valve deterioration. RESILIA™ tissue has exhibited reduced calcification in pre-clinical and early clinical studies. This study evaluated the 5-year clinical and haemodynamic outcomes of an aortic valve with this tissue. METHODS: This was a prospective, non-randomized, single-arm study of 133 patients implanted with a RESILIA aortic bioprosthesis between July 2011 and February 2013 at 2 sites in Poland. Clinical outcomes and haemodynamic performance were assessed annually for 5 years post-implant. Safety events were adjudicated by a Clinical Events Committee and echocardiographic data were assessed by an independent core laboratory. RESULTS: Mean patient age was 65.3 ± 13.5 years, with 34 patients (25.6%) ≤60. The mean follow-up was 4.2 ± 1.5 years. Early (≤30 days) and late (>30 days) all-cause mortality were 2.3% (N = 3) and 3.2%/late patients-years (N = 18) respectively. Early events included thromboembolism in 3 patients (2.3%). Late valve-related events included endocarditis in 1 patient, which led to explant, and valve thrombosis in another patient. There were no events of structural valve deterioration throughout the study. At 5 years, mean gradient was 14.8 ± 7.6 mmHg and effective orifice area was 1.4 ± 0.5 cm2, a marked improvement over baseline values. All New York Heart Association class III patients and most class II patients at baseline had improved classifications at 5 years. CONCLUSIONS: The bioprosthesis with RESILIA tissue demonstrated a good safety profile with excellent haemodynamic performance over 5 years of follow-up. These encouraging outcomes warrant additional investigation of this novel tissue. CLINICAL TRIAL REGISTRATION NUMBER: NCT01651052.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Bartus K, Litwinowicz R, Bilewska A, et al. Final 5-year outcomes following aortic valve replacement with a RESILIA™ tissue bioprosthesis. Eur J Cardiothorac Surg. 2021. PMID: 33141188. doi:10.1093/ejcts/ezaa311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。